insulin icodec/semaglutide Icodec + Semaglutide (IcoSema / Kyinsu) A fixed-dose combination of: Basal insulin icodec (ultra-long acting) GLP-1 receptor agonist semaglutide Designed for once-weekly subcutaneous injection Current Status Completed Phase 3 trials (COMBINE CGM-derived postprandial glucose with IcoSema

A comprehensive baseline assessment helps monitor both hormonal and metabolic responses effectively

Research applications span metabolic physiology, cardiac function, skeletal muscle energetics, neurological studies, and reproductive biology

Gas, bloating, and burping Flatulence, abdominal distension, and burping are all reported with oral semaglutide

& Thornhill, B

doi: 10.1007/s00125-010-2028-x 168 LiljedahlLPedersenMHMcGuireJNJamesP

Here are the top warnings based on its clinical trial: Risk of Thyroid C-Cell Tumors: Patients initial work up and maintanence physical exam should include the thyroid exam and neck imaging